BidaskClub cut shares of Sarepta Therapeutics (NASDAQ:SRPT) from a buy rating to a hold rating in a research report released on Saturday, January 6th.
A number of other analysts have also recently commented on SRPT. Leerink Swann reissued an outperform rating and issued a $66.00 price target on shares of Sarepta Therapeutics in a research report on Saturday, September 30th. Instinet restated a buy rating and issued a $84.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 2nd. JPMorgan Chase & Co. restated a hold rating on shares of Sarepta Therapeutics in a report on Monday, September 25th. Janney Montgomery Scott initiated coverage on shares of Sarepta Therapeutics in a report on Wednesday, January 3rd. They issued a buy rating and a $75.00 price objective for the company. Finally, Credit Suisse Group restated an outperform rating and issued a $81.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 2nd. Two analysts have rated the stock with a sell rating, four have issued a hold rating and eighteen have given a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $63.88.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at $60.15 on Friday. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $3,890.00, a PE ratio of -29.49 and a beta of 1.37. Sarepta Therapeutics has a 12 month low of $26.26 and a 12 month high of $62.85.
In other Sarepta Therapeutics news, SVP Shamim Ruff sold 10,000 shares of the stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $55.00, for a total transaction of $550,000.00. Following the completion of the transaction, the senior vice president now owns 37,045 shares of the company’s stock, valued at approximately $2,037,475. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Douglas S. Ingram bought 38,138 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The shares were acquired at an average price of $52.44 per share, for a total transaction of $1,999,956.72. Following the completion of the transaction, the chief executive officer now directly owns 420,196 shares in the company, valued at approximately $22,035,078.24. The disclosure for this purchase can be found here. 9.60% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of SRPT. Ameritas Investment Partners Inc. raised its position in Sarepta Therapeutics by 6.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 271 shares during the period. Cubist Systematic Strategies LLC raised its position in Sarepta Therapeutics by 116.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 2,474 shares during the period. Ladenburg Thalmann Financial Services Inc. raised its position in Sarepta Therapeutics by 140.9% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,262 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 2,493 shares during the period. Fox Run Management L.L.C. purchased a new stake in Sarepta Therapeutics in the 3rd quarter worth about $204,000. Finally, Bayesian Capital Management LP purchased a new stake in Sarepta Therapeutics in the 2nd quarter worth about $206,000. 82.02% of the stock is currently owned by institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.